Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).

Mohammad Shafi KuchaySonal KrishanSunil Kumar MishraKhalid Jamal FarooquiManish Kumar SinghJasjeet Singh WasirBeena BansalParjeet KaurGanesh JevalikarHarmendeep Kaur GillNarendra Singh ChoudharyAmbrish Mithal

Published in: Diabetes care (2018)

When included in the standard treatment for type 2 diabetes, empagliflozin reduces liver fat and improves ALT levels in patients with type 2 diabetes and NAFLD.

Keyphrases

type diabetes
adipose tissue
fatty acid
clinical trial
study protocol
cardiovascular disease
glycemic control
randomized controlled trial
phase ii
metabolic syndrome
combination therapy
open label